

Date: May 26, 2022

To: All EIMPRIS team members

From: Jesse McCullough, EIMPRIS Study Team

Re: **Memo #1: Study Drug and Start-up Supplies**

Congratulations on being among the first sites chosen to enroll patients in the EIMPRIS study (also known as ESR 22-21698). We look forward to a very exciting and fast-paced enrollment process.

Before you can treat any patients, the following tasks **must** be completed:

- Submitted all required regulatory documents
- Completed online training for all site coordinators related to the **protocol and technologies**
- Received approval from the IRB (Advarra)

Once all requirements have been completed, you will receive a Study Activation Letter from Julie Garrett allowing you to begin the study.

In parallel to completing the regulatory requirements, supplies are being distributed to your site.

1. Several supplies will be arriving at your site in the next 3 business days including:

- a. Study drug will be delivered to your site on **Friday, May 27! You will receive enough drug to treat 10 patients.** The study drug was shipped from Fisher Clinical Services in Allentown, PA via FedEx.
  - i. ACTION ITEM: **The study drug must be refrigerated immediately upon receipt.**
  - ii. ACTION ITEM: Upon receipt of the drug, please complete the attached Drug Disposition Form and upload the document to the shared drive you used for your regulatory documents.
  - iii. ACTION ITEM: A USB temperature monitoring device will be included in the packaging. Follow the instructions including with the drug for cold chain monitoring and returning the shipping containers. Copies of those instructions are attached.
  - iv. When you need more drug, please send us an email and we will ship via FedEx overnite.
- b. You will also be receiving, via FedEx, on **Friday, May 27**, a box of supplies from MediMergent which will include:

- i. 10x COVID-19 home test kits with 2 tests per kit (one test performed at time of enrollment and one for the patient to take home),
    - ii. 60x 8.5 ml yellow top ACD tubes for t-cell assay,
    - iii. 10x 3.5 ml gold top SST tubes for AZD7442 serum concentration and
    - iv. 50x crystal vials to place the AZD7442 serum into after collection and spin down.
  - c. LabCorp will be dropping off 60x 6.5 ml gold-top SST tubes to your office on **Tuesday, May 31**. These are for the RBD-IgG antibody levels.
2. Other supplies coming for your site include:
  - a. Labels to use for all blood draws, syringes, crystal vials, etc. will be delivered next week.
  - b.
  - c. Isoplexis will be sending you the kits to ship the t-cell samples directly to them. The actual dates will be communicated once available. These supplies are not needed until an enrolled patient reaches day 30. You are encouraged to begin enrollment now.
3. All sites should have received a Lenovo Chromebook.
  - a. ACTION ITEM: Make sure the Chromebook is plugged in to maintain a constant charge
  - b.
  - c. ACTION ITEM: Make sure the Chromebook is connected to your Wi-Fi network as per the attached instructions.
  - d.
  - e. Remember you will need the Chromebook ready for your patients to enroll in EIMPRIS and complete their baseline surveys. We recommend you use the 60-minute post-administration observation period to allow your patients to complete the baseline survey. Surveys can be accessed from the APPS menu on the Chromebook. These surveys are equivalent to the eCRFs.
4. The **Provider Training** website ([provider.eimpris.com](http://provider.eimpris.com)) will be updated on **May 31** to include 2 new videos. These videos will be found under the TECHNOLOGY TRAINING tab on the left menu.
  - a. The PROGRAM DASHBOARD TRAINING VIDEO addresses the steps necessary to enroll a patient.
  - b. The USING THE EIMPRIS PATIENT APP video addresses how the survey questions are answered.

- c. You are encouraged to review these videos promptly to enhance your training on the EIMPRIS study.
5. The **Participant Training** website (participant.eimpris.com) will be updated on **May 31** with the USING THE EIMPRIS PATIENT APP video.
- a. This video will present information to the patient about using the EIMPRIS app and specifically how to complete the patient experience surveys. The training website can be accessed from any internet connected device.
  - b. The participant training website contains a video which provide important information related to the EIMPRIS opportunity and the value that it brings to the lives of cancer patients. Please encourage your patients to view this engaging video.

Please let us know what we can do to help make EIMPRIS successful for you and your patients. We are all looking forward to a most exciting project!

Feel free to reach out to us any time at [eimpris@eimpris.com](mailto:eimpris@eimpris.com) or call us at **800-757-7345**.